Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Ongoing Brand or Portfolio Management

Sponsored by

Finalist

Remicade in IBD

MSD


Summary of work

Remicade (infliximab) is a biologic used in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). Remicade is given as an intravenous infusion while our only competitor (Humira) is given as a subcutaneous injection.

From 2009 we have focused on both establishing Remicade in the treatment pathway for CD and differentiating Remicade from the competition.

Our objectives have been on growth, market share and campaign implementation.

Three core initiatives have been consistently evolved throughout 2009–2011 to enable MSD to achieve our objectives. These are:

  • Market access propositions
    - Identification of service issues and solutions, "lean" solutions to capacity issuesand commercial proposition
  • Medical education
    - Best practice, clinical and non-clinical developments
  • Promotional campaign
    - Focusing on establishing treatment pathways and improving patient outcomes

Our learnings include the importance of customer insight in the development and evolution of these core initiatives. The patient should be at the centre of the core campaign with the focus on improving patient outcomes and experience. This should be consistent in our market access and medical propositions and also our sales promotional campaign.

Incorporating the sales team in the development of the campaigns has ensured "buy-in" and has resulted in effective implementation of the campaign.

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics